Lygature’s Post

Precision oncology company Flindr Therapeutics is pleased to announce the close of its €20million Series A financing, which will be used to advance its first-in-class small molecule inhibitor of RNF31.   Flindr combines world class science and expertise in translational biology, cancer target identification, immune-oncology and small molecule oncology #drugdevelopment. It is led by an expert team of established industry leaders and utilizes the ‘ImmunoGram Drug Discovery Engine’ pioneered in the labs of the highly-regarded The Netherlands Cancer Institute (NKI) and the Oncode Institute.   The Company will use the funds to advance its lead program, a small molecule inhibitor of #RNF31 to IND, develop an exciting second program, and broaden its pipeline. Flindr is well placed to transform the precision oncology space, with the ability to discover and develop unique #precisiononcology therapeutics, based on novel targets, to eradicate tumors in specific patient populations.   The financing was led by V-Bio Ventures, along with a strong international syndicate comprised of Johnson & Johnson Innovation JJDC Inc, Qbic Fund | Venture Capital, Flanders Future Tech Fund (PMV), and Curie Capital BV, which were also joined by seed investors Oncode Oncology Bridge Fund (Oncode Institute), Swanbridge Capital, and Brabantse Ontwikkelings Maatschappij (BOM).   For more information, see the full press release via the link in the comments below.   #oncology #biology #financing

Precision oncology company Flindr Therapeutics is pleased to announce the close of its €20million Series A financing, which will be used to advance its first-in-class small molecule inhibitor of RNF31.   Flindr combines world class science and expertise in translational biology, cancer target identification, immune-oncology and small molecule oncology #drugdevelopment. It is led by an expert team of established industry leaders and utilizes the ‘ImmunoGram Drug Discovery Engine’ pioneered in the labs of the highly-regarded The Netherlands Cancer Institute and the Oncode Institute.   The Company will use the funds to advance its lead program, a small molecule inhibitor of #RNF31 to IND, develop an exciting second program, and broaden its pipeline. Flindr is well placed to transform the precision oncology space, with the ability to discover and develop unique #precisiononcology therapeutics, based on novel targets, to eradicate tumors in specific patient populations.   The financing was led by V-Bio Ventures, along with a strong international syndicate comprised of Johnson & Johnson Innovation JJDC Inc, Inc, Qbic Fund | Venture Capital, Flanders Future Tech Fund (PMV), and Curie Capital BV, which were also joined by seed investors Oncode Oncology Bridge Fund (Oncode Institute), Swanbridge Capital, and Brabantse Ontwikkelings Maatschappij (BOM).   For more information, see the full press release via the link in the comments below.   #oncology #biology #financing

📢Biotech Funding Update📢💷💵💶 Myricx Bio has just secured a hefty £90M ($114M) in Series A funding 🤯 - a significant milestone for UK innovation 📈🥳. Novo Holdings and Abingworth are leading the charge, with British Patient Capital, Eli Lilly & Company, and familiar faces Sofinnova Partners and Brandon Capital on board. It has been a few difficult years for the industry, and I am sure this positive news will be widely welcomed by founders and investors alike. 🚀💰 Under the leadership of CEO Dr. Robin Carr and co-founders, Myricx Bio is pioneering a revolutionary class of payloads for next-gen cancer treatments. Their focus? NMT inhibitors that pack a punch against cancer cells while sparing patients from resistance issues common with current ADCs. The potential here is enormous - complete tumour regressions and broad efficacy across cancer models, all while maintaining a patient-friendly profile. It's no wonder the biotech community is abuzz with the promise Myricx holds! 🧬🛡️ For those passionate about making a tangible difference in oncology, stay tuned - we just might be witnessing a breakthrough in cancer therapy. 🤞🏾👩🔬👨🔬🌟 Exciting times for humanity! 🎆 (I will share a link to the article in the comment section) Dynamic Minds Recruitment #Biotech #Innovation #Oncology

🔬 Delphia Therapeutics Raises $67M to Pioneer "Activation Lethality" Cancer Treatment TL;DR: • Revolutionary approach targets cancer by overactivating cell signaling pathways • Led by industry veteran Kevin Marks • Backed by GV, Nextech Invest, Polaris Innovation Fund • Clinical trials on horizon While synthetic lethality has dominated cancer research headlines, Delphia is charting a bold new course. Their "activation lethality" approach essentially overdrives cancer cells to self-destruct - imagine pushing a car's accelerator past its limits until the engine fails. The science, rooted in research from the Broad Institute of MIT and Harvard, presents cancer cells with an entirely new challenge to overcome. This could be game-changing for drug resistance issues that plague current treatments. David Schenkein, former Agios CEO and GV life science investment lead, calls it "one of the most innovative approaches in cancer drug development." What's next? The fresh capital positions Delphia to advance toward clinical trials, though specific targets remain under wraps. 💭 What are your thoughts on this novel approach to cancer treatment? Could "activation lethality" be the next breakthrough we've been waiting for? #BiotechInnovation #CancerResearch #DrugDevelopment #LifeSciences #intelligencesimplified #pharma #biotech #biodatastudio

🔬 Breaking Biotech News: FogPharma Raises $145M Series E for Revolutionary Cancer Drug Development TL;DR: • Secured $145M led by Nextech Invest • Advancing FOG-001 through Phase 1/2 trials • Targeting beta-catenin protein for tumor inhibition • Notable backing from RA Capital, Arch Venture Partners, GV Former J&J executive Mathai Mammen leads the charge as CEO, joined by veteran biotech investor Alexis Borisy on the board. The funding arrives amid a shifting biotech landscape where companies are strategically choosing to remain private longer. What sets this apart: FogPharma's innovative "Helicon" polypeptide drugs are tackling previously undruggable targets, particularly in colorectal cancer. The pipeline extends to prostate, ovarian, and pancreatic cancer programs. Key Quote: "This financing enables us to accelerate FOG-001's clinical development while strengthening our discovery efforts against other compelling intracellular targets." - Mathai Mammen, CEO 💭 What are your thoughts on the evolving private funding landscape in biotech? Share your insights below. #BiotechNews #CancerResearch #VentureFunding #Innovation #Healthcare #intelligencesimplified #pharma #biotech #biodatastudio

Happy to share this interesting article from Sifted featuring our Debiopharm Innovation Fund's strategic investments in Genialis and Nucleai! Their collaboration with Debiopharm is crucial, as it provides the resources, expertise, and network needed to accelerate breakthroughs in oncology drug development and enhance the success of cancer treatments! 🚀 #AI #HealthcareInnovation #CancerResearch #PrecisionMedicine #ClinicalTrial

In the ever-evolving landscape of healthcare, innovation fuels progress. The recent announcement from the Asian Fund for Cancer Research highlights the vital role of competitive funding in advancing cancer treatment. Concarlo Therapeutics, under the leadership of Stacy Blain, exemplifies how strategic vision can drive meaningful change. This recognition not only underscores the importance of investment in innovation but also inspires us as marketers to showcase these breakthroughs. Let’s harness these narratives to engage our stakeholders and elevate our strategies. #HealthcareMarketing #Innovation

🔬 German Biotech Tubulis Raises €128M for Next-Gen Cancer Therapeutics TL;DR: • €128M ($140M) funding secured • Clinical trials for 2 ADC candidates in 2024 • U.S. expansion planned • Backed by EQT Life Sciences, Nextech Invest + 12 investors Exciting developments in the ADC space! Tubulis is advancing their innovative antibody-drug conjugate platform with a massive Series B2 round. Their technology customizes each ADC component for targeted cancer treatment, addressing key limitations in current approaches. Key Programs: • NaPi2b targeting (ovarian/lung cancers) • 5T4 targeting (multiple cancer types) • 4 publicly disclosed candidates • 2 approaching clinical phase Strategic moves: ✓ BMS collaboration ongoing ✓ U.S. subsidiary launching ✓ AACR data presentation in April ✓ Phase 1/2 trials on horizon This raise signals growing confidence in next-gen ADC platforms. As someone tracking biotech innovations, I'm particularly impressed by their design flexibility approach. 💭 What are your thoughts on the ADC renaissance we're seeing? Are customizable platforms the future of targeted cancer therapeutics? #Biotech #CancerResearch #DrugDevelopment #ADC #BiotechInnovation #intelligencesimplified #pharma #biotech #biodatastudio

Arsenal Biosciences, Inc. has secured $325M in Series C funding, a massive boost for its mission to revolutionize cancer treatment with programmable T-cell therapies. Focused on solid tumors like ovarian and kidney cancers, ArsenalBio’s approach stands out in a crowded field, where many peers have pivoted away from oncology. Led by CEO Ken Drazan, whose experience spans roles at Grail and Johnson & Johnson, the company has made significant progress. With two industry partnerships already in place and clinical trials underway, ArsenalBio is well-positioned against competitors. Notably, it’s tackling the complex challenge of treating solid tumors—an area where other cell therapy developers have struggled. Among its leading candidates, AB-1015 is being tested for ovarian cancer resistant to other treatments, while AB-2100 is in early trials for clear cell renal cell carcinoma. With major backers like Regeneron, Nvidia, and Bristol Myers Squibb, ArsenalBio is setting the stage for breakthroughs in an area that has seen limited success. In a year where venture funding has been scarce, this achievement not only reflects confidence in ArsenalBio's vision but also underscores the importance of innovation and perseverance in the biotech industry. Excited to see how ArsenalBio will continue to push the boundaries of what's possible in cancer therapy! #Biotech #CancerResearch #Innovation #VentureCapital #CellTherapy #Solidtumors

🔬 Clasp Therapeutics Raises $150M Series A for Next-Gen Cancer Immunotherapies TL;DR: • $150M funding led by Catalio Capital, Third Rock Ventures, and Novo Holdings • Developing precision bispecific T-cell engagers • Led by ex-Surface Oncology CEO Robert Ross • Based on groundbreaking research from Johns Hopkins University Clasp is revolutionizing cancer treatment by engineering "bispecific" T-cell engagers that precisely target tumor cells while sparing healthy tissue. Their innovative approach matches drug candidates to specific patient immune signatures and tumor mutations, potentially enabling higher dosing and better efficacy. Key Differentiators: • Off-the-shelf solution vs. personalized cell therapies • Enhanced safety profile through precise targeting • Broader therapeutic window for optimal dosing • Dual locations in Cambridge, MA and Rockville, MD The company plans to focus on generating robust clinical data before considering public markets, demonstrating a strategic long-term vision for development. 💭 What are your thoughts on the future of bispecific therapeutics in oncology? Share your insights below. #BiotechNews #CancerResearch #Immunotherapy #BiotechStartup #VentureCapital #intelligencesimplified #pharma #biotech #biodatastudio